{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.5.6.6', 'Week 9', 'Collect predose blood samples for immunogenicity and PK testing.', 'Contact IWRS to Obtain study medication vial assignment and to determine volume of', 'study drug to be administered from EDC.', 'Collect blood samples for PK analyses at the end of the infusion.', '9.5.6.7', 'Week 12', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', 'Contact IWRS to oObtain study medication vial assignment and to determine volume of', 'study drug to be administered from EDC.', '9.5.6.8', 'Week 15', 'Contact IWRS to obtain study medication vial assignment and to determine volume of', 'study drug to be administered from EDC.', '9.5.6.9', 'Week 18', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', 'Contact IWRS to Obtain study medication vial assignment and to determine volume of', 'study drug to be administered from EDC.', '9.5.6.10 Week 21', 'Contact IWRS to Obtain study medication vial assignment and to determine volume of', 'study drug to be administered from EDC.', '9.5.6.11 Week 24/Premature Withdrawal - Treatment Period (EOT)', 'Week 24EOT is the final visit of the Treatment Period. and will occur 3 weeks after the last', 'infusion. Study drug is not administered.', 'Collect blood sample for immunogenicity testing (only subjects who complete the', 'Treatment Period, not those who prematurely discontinue study drug', 'administration).', 'Collect blood sample for PK analyses (only subjects who complete the Treatment', 'Period, not those who prematurely discontinue study drug administration).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 25 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Contact IWRS to register the EOT Visit.', 'Subjects who were proptosis non-responders in Study HZNP-TEP-301 will enter the', 'Follow-Up Period and will be instructed to return to the clinic in one month for the first', 'follow-up visit. Subjects who relapsed during the Follow-Up Period of HZNP-TEP-301 and', 'chose to enter this extension study will be discharged from the study following completion of the', 'EOT assessments (they will not participate in the Follow-Up Period). Subjects who were', 'proptosis non responders in Study HZNP TEP 301 will enter the Follow Up Period and will be', 'instructed to return to the clinic in one month for the first follow up visit.', '9.5.6.12 Month 7 - Follow-Up Period', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', '9.5.6.13 Month 9 - Follow-Up Period', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', '9.5.6.14 Month 12', '9.5.6.14.1', 'Month 12/Premature WithdrawalEOS - Follow-Up Period for Proptosis', 'Non-responders in Study HZNP-TEP-301', 'Obtain blood samples for hematology and chemistry (including thyroid, glucose, and', 'HbA1c) analysis.', 'Collect urine sample for urinalysis.', 'Collect urine sample for a pregnancy test for females of childbearing potential if the', 'subject discontinued from the study prior to Month 9 of the Follow-Up Period.', 'Collect blood sample for immunogenicity testing.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform 12-lead ECG.', 'Perform physical and ophthalmic examinations, including vital signs.', 'Measure weight.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 26 of 118']\n\n###\n\n", "completion": "END"}